RxDoctor Payments Data

Clara Coutee

Family · Marksville, LANPI 1962406884

Payments from drug & device makers

$2,447in general payments, 2019–2025

Across 154 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$518
  • AbbVie$370
  • Amgen$240
  • AstraZeneca$235
  • Lilly USA, LLC$174
  • Novo Nordisk$170
  • plus $740 from 19 others

What the payments were for

  • Food & beverage$2,447100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,447 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin126$113,505
OzempicSemaglutide74$75,355
TrulicityDulaglutide66$72,704
MounjaroTirzepatide53$69,528
EliquisApixaban60$55,512
LinzessLinaclotide61$50,775
TradjentaLinagliptin44$34,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,737
EntrestoSacubitril/Valsartan21$19,661
JanuviaSitagliptin Phosphate12$18,169
MyrbetriqMirabegron24$17,767
RybelsusSemaglutide13$11,887
SymbicortBudesonide/Formoterol Fumarate30$10,466
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,371
Diclofenac Sodium129$5,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$174$142,233119 claims
Novo NordiskOzempic, Rybelsus$170$87,24287 claims
PfizerEliquis$27$55,51260 claims
AbbVieLinzess$370$50,77561 claims
GSKTrelegy Ellipta, Anoro Ellipta$518$26,94433 claims
MerckJanuvia$15$18,16912 claims
Astellas Pharma US IncMyrbetriq$29$17,76724 claims
AstraZenecaSymbicort$235$10,46630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Marksville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →